← All stocks

Enliven Therapeutics, Inc.

ELVN Scheduled selling only
CIK 0001672619 #1481 in the set updated 22 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$554.76K
$0.00 on a plan · $554.76K straight out of an exercise
Sold at will
$0.00
0 of 6 sales
Net
−$554.76K
$0.00 against sales at will

By person

10 insiders · 6 transactions

There is no salary here to measure against. Enliven Therapeutics, Inc.'s chief executive is paid a token, so dividing a holding by it says nothing.

Which is why this company is in neither direction of the chief executive filter on the transactions page. A stake that cannot be expressed as a multiple is not the same thing as a small one.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Hohl Benjamin
CHIEF FINANCIAL OFFICER
$303.00K (3) scheduled
−$303.00K
38,000
0.0519%
$1.96M
Collins Helen Louise
CHIEF MEDICAL OFFICER
$251.75K (3) scheduled
−$251.75K
25,000
0.0341%
$1.29M
ORBIMED ADVISORS LLC entity
10% owner
6,555,102
8.95%
$337.47M
−14.8%
Kintz Samuel
PRESIDENT AND CEO
890,392
1.22%
$45.84M
−15.0%
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
758,938
1.04%
$39.07M
−29.6%
Patel Anish
CHIEF OPERATING OFFICER
235,011
0.3207%
$12.10M
−31.7%
Heyman Richard A.
Director
146,320
0.1997%
$7.53M
−13.4%
Kunkel Lori Anne
Director
41,884
0.0572%
$2.16M
−8.8%
Ballal Rahul D.
Director
22,341
0.0305%
$1.15M
0.0%
Derynck Mika K
Director
0
0.0000%
$0.00

Nothing of that kind in this period.

What was left out

Form 4 filings counted 2
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 6
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 8,982
History held since 16 Mar 2020